 Douglas Ney
Concepts (141)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 17 | 2021 | 1014 | 2.160 |
Why?
| | Central Nervous System Neoplasms | 4 | 2023 | 127 | 1.390 |
Why?
| | Glioblastoma | 8 | 2019 | 263 | 1.070 |
Why?
| | Neurology | 3 | 2019 | 88 | 0.880 |
Why?
| | Mycosis Fungoides | 2 | 2018 | 62 | 0.760 |
Why?
| | Quality Improvement | 2 | 2018 | 953 | 0.740 |
Why?
| | Lymphoma | 3 | 2023 | 178 | 0.730 |
Why?
| | Radiotherapy, Intensity-Modulated | 3 | 2015 | 128 | 0.690 |
Why?
| | Oligodendroglioma | 3 | 2021 | 15 | 0.670 |
Why?
| | Chemoradiotherapy | 3 | 2015 | 199 | 0.660 |
Why?
| | Health Services | 1 | 2018 | 108 | 0.590 |
Why?
| | Dacarbazine | 5 | 2016 | 102 | 0.510 |
Why?
| | Skin Neoplasms | 2 | 2018 | 763 | 0.450 |
Why?
| | Quality of Health Care | 1 | 2018 | 583 | 0.450 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2023 | 1370 | 0.450 |
Why?
| | Delivery of Health Care | 1 | 2018 | 850 | 0.380 |
Why?
| | Cerebral Ventricle Neoplasms | 1 | 2010 | 4 | 0.370 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2010 | 72 | 0.360 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2010 | 64 | 0.350 |
Why?
| | Antineoplastic Agents, Alkylating | 3 | 2016 | 69 | 0.350 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 82 | 0.340 |
Why?
| | Meningioma | 1 | 2010 | 82 | 0.330 |
Why?
| | Meningeal Neoplasms | 1 | 2010 | 90 | 0.330 |
Why?
| | Medical Oncology | 2 | 2021 | 226 | 0.310 |
Why?
| | Astrocytoma | 2 | 2021 | 111 | 0.310 |
Why?
| | Lymphoproliferative Disorders | 1 | 2023 | 45 | 0.220 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2023 | 72 | 0.210 |
Why?
| | Aged | 13 | 2023 | 19362 | 0.190 |
Why?
| | Survival Rate | 3 | 2015 | 1681 | 0.190 |
Why?
| | Middle Aged | 14 | 2023 | 27140 | 0.180 |
Why?
| | Hashimoto Disease | 1 | 2020 | 9 | 0.180 |
Why?
| | Meningoencephalitis | 1 | 2020 | 24 | 0.180 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2020 | 84 | 0.180 |
Why?
| | Fatal Outcome | 2 | 2018 | 282 | 0.180 |
Why?
| | Humans | 25 | 2023 | 116801 | 0.170 |
Why?
| | Bevacizumab | 3 | 2015 | 120 | 0.170 |
Why?
| | Oncologists | 1 | 2019 | 31 | 0.170 |
Why?
| | Chemotherapy, Adjuvant | 3 | 2015 | 357 | 0.170 |
Why?
| | Neurologic Examination | 1 | 2019 | 120 | 0.160 |
Why?
| | Hospice and Palliative Care Nursing | 1 | 2019 | 68 | 0.160 |
Why?
| | Encephalitis | 1 | 2020 | 127 | 0.160 |
Why?
| | Patient Care | 1 | 2018 | 105 | 0.150 |
Why?
| | Male | 15 | 2020 | 56636 | 0.150 |
Why?
| | Alzheimer Disease | 1 | 2022 | 474 | 0.140 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2012 | 440 | 0.140 |
Why?
| | Follow-Up Studies | 4 | 2015 | 4516 | 0.140 |
Why?
| | Prognosis | 3 | 2015 | 3384 | 0.140 |
Why?
| | Neurosurgical Procedures | 1 | 2017 | 163 | 0.140 |
Why?
| | Rituximab | 2 | 2023 | 153 | 0.130 |
Why?
| | Radiotherapy | 1 | 2016 | 186 | 0.130 |
Why?
| | Education, Medical, Graduate | 1 | 2019 | 381 | 0.130 |
Why?
| | Combined Modality Therapy | 3 | 2016 | 1156 | 0.130 |
Why?
| | Neoplasm Staging | 2 | 2015 | 1213 | 0.120 |
Why?
| | Seizures | 1 | 2017 | 347 | 0.120 |
Why?
| | Societies, Medical | 1 | 2018 | 680 | 0.120 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2014 | 188 | 0.120 |
Why?
| | Eosinophilia | 1 | 2015 | 185 | 0.110 |
Why?
| | Adult | 10 | 2017 | 30930 | 0.110 |
Why?
| | Curriculum | 1 | 2019 | 871 | 0.110 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2012 | 38 | 0.100 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2632 | 0.100 |
Why?
| | Prospective Studies | 4 | 2015 | 6371 | 0.090 |
Why?
| | Female | 12 | 2019 | 60542 | 0.090 |
Why?
| | Disease Progression | 3 | 2019 | 2466 | 0.090 |
Why?
| | Treatment Outcome | 5 | 2021 | 9212 | 0.090 |
Why?
| | Mutation | 2 | 2012 | 3408 | 0.090 |
Why?
| | Receptors, Platelet-Derived Growth Factor | 1 | 2009 | 13 | 0.080 |
Why?
| | Chromosomes, Human, Pair 19 | 1 | 2009 | 24 | 0.080 |
Why?
| | Internship and Residency | 1 | 2019 | 979 | 0.080 |
Why?
| | Aged, 80 and over | 3 | 2023 | 6478 | 0.080 |
Why?
| | Remission Induction | 1 | 2009 | 245 | 0.080 |
Why?
| | Disease-Free Survival | 1 | 2010 | 643 | 0.080 |
Why?
| | Genes, p53 | 1 | 2009 | 64 | 0.080 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2009 | 82 | 0.080 |
Why?
| | Chromosome Deletion | 1 | 2009 | 94 | 0.080 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2009 | 71 | 0.080 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2012 | 886 | 0.080 |
Why?
| | Angiogenesis Inhibitors | 1 | 2009 | 216 | 0.080 |
Why?
| | Ependymoma | 1 | 2009 | 165 | 0.080 |
Why?
| | Chromosome Mapping | 1 | 2009 | 499 | 0.080 |
Why?
| | Age Factors | 2 | 2014 | 2955 | 0.070 |
Why?
| | Retrospective Studies | 6 | 2023 | 12740 | 0.070 |
Why?
| | Multiple Sclerosis | 1 | 2012 | 378 | 0.070 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2010 | 267 | 0.070 |
Why?
| | Recurrence | 1 | 2009 | 960 | 0.070 |
Why?
| | Postoperative Complications | 1 | 2017 | 2180 | 0.070 |
Why?
| | Alleles | 1 | 2009 | 820 | 0.070 |
Why?
| | Diagnosis, Differential | 1 | 2010 | 1346 | 0.070 |
Why?
| | ErbB Receptors | 1 | 2009 | 567 | 0.070 |
Why?
| | Immunotherapy | 1 | 2009 | 491 | 0.070 |
Why?
| | DNA Methylation | 1 | 2009 | 501 | 0.060 |
Why?
| | Antibodies, Monoclonal | 1 | 2009 | 1271 | 0.060 |
Why?
| | Cytarabine | 1 | 2023 | 53 | 0.060 |
Why?
| | Herpesvirus 4, Human | 1 | 2023 | 124 | 0.050 |
Why?
| | Quality of Life | 1 | 2013 | 2353 | 0.050 |
Why?
| | Methotrexate | 1 | 2023 | 228 | 0.050 |
Why?
| | Central Nervous System | 1 | 2023 | 242 | 0.050 |
Why?
| | Activities of Daily Living | 1 | 2023 | 351 | 0.050 |
Why?
| | Hope | 1 | 2019 | 12 | 0.040 |
Why?
| | Consensus | 1 | 2021 | 520 | 0.040 |
Why?
| | Clinical Decision-Making | 1 | 2021 | 275 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2023 | 675 | 0.040 |
Why?
| | Antineoplastic Agents | 1 | 2009 | 1946 | 0.040 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 155 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2021 | 683 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2021 | 1836 | 0.040 |
Why?
| | Neuroimaging | 1 | 2019 | 252 | 0.040 |
Why?
| | Incidence | 1 | 2023 | 2373 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1226 | 0.030 |
Why?
| | Time Factors | 2 | 2021 | 6248 | 0.030 |
Why?
| | Intraoperative Complications | 1 | 2017 | 128 | 0.030 |
Why?
| | Child, Preschool | 1 | 2010 | 9289 | 0.030 |
Why?
| | Anticonvulsants | 1 | 2017 | 182 | 0.030 |
Why?
| | Marital Status | 1 | 2014 | 43 | 0.030 |
Why?
| | SEER Program | 1 | 2014 | 206 | 0.030 |
Why?
| | Biopsy | 1 | 2017 | 1059 | 0.030 |
Why?
| | Palliative Care | 1 | 2019 | 626 | 0.030 |
Why?
| | Karnofsky Performance Status | 1 | 2013 | 36 | 0.030 |
Why?
| | Biomarkers | 1 | 2022 | 3540 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2014 | 1248 | 0.020 |
Why?
| | Databases, Factual | 1 | 2016 | 1180 | 0.020 |
Why?
| | Tumor Burden | 1 | 2012 | 272 | 0.020 |
Why?
| | PTEN Phosphohydrolase | 1 | 2012 | 143 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2012 | 372 | 0.020 |
Why?
| | Dexamethasone | 1 | 2012 | 307 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2017 | 3120 | 0.020 |
Why?
| | Reoperation | 1 | 2012 | 535 | 0.020 |
Why?
| | Sex Factors | 1 | 2014 | 1749 | 0.020 |
Why?
| | Neuropsychological Tests | 1 | 2013 | 954 | 0.020 |
Why?
| | Young Adult | 2 | 2017 | 10643 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2012 | 456 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 3016 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2009 | 830 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2009 | 960 | 0.020 |
Why?
| | Adolescent | 2 | 2017 | 18154 | 0.020 |
Why?
| | Cohort Studies | 1 | 2016 | 5047 | 0.020 |
Why?
| | Cognition | 1 | 2013 | 997 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2009 | 664 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2012 | 2232 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2012 | 3101 | 0.010 |
Why?
| | United States | 1 | 2014 | 12337 | 0.010 |
Why?
|
|
Ney's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|